Get the Stockscreener App
0.7596
2.30%
0.0171
After Hours:
.76
0.00043
+0.06%
Zyversa Therapeutics Inc stock is traded at $0.7596, with a volume of 43,219.
It is up +2.30% in the last 24 hours and down -37.74% over the past month.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
See More
Previous Close:
$0.7425
Open:
$0.7338
24h Volume:
43,219
Relative Volume:
0.05
Market Cap:
$815.93K
Revenue:
-
Net Income/Loss:
$-21.33M
P/E Ratio:
-0.00668
EPS:
-113.7479
Net Cash Flow:
$-9.12M
1W Performance:
-7.39%
1M Performance:
-37.74%
6M Performance:
-66.54%
1Y Performance:
-90.63%
1-Day Range:
$0.70
$0.7599
1-Week Range:
$0.70
$0.839
52-Week Range:
$0.70
$8.71
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Name
Zyversa Therapeutics Inc
Sector
Industry
Phone
908-370-5102
Address
217 W. MAIN STREET, SOMERVILLE
Compare ZVSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.7596 | 815.93K | 0 | -21.33M | -9.12M | -113.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Zyversa Therapeutics Inc Stock (ZVSA) Latest News
ZyVersa’s IC 100 shows promise in OAC treatment study By Investing.com - Investing.com South Africa
ZyVersa’s IC 100 shows promise in OAC treatment study - Investing.com India
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ... - The Bakersfield Californian
ZyVersa Therapeutics Highlights Data Published in the - GlobeNewswire
Breakthrough: New Drug Could Transform 50% Survival Rate in Obesity Heart Disease - StockTitan
ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday - Defense World
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6% - Defense World
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline - Investing.com Australia
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline By Investing.com - Investing.com South Africa
ZyVersa’s Alzheimer’s treatment shows promise in studies By Investing.com - Investing.com Australia
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition - TipRanks
ZyVersa’s Alzheimer’s treatment shows promise in studies - Investing.com India
ZyVersa Therapeutics Highlights Data Demonstrating - GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model - GlobeNewswire
Breakthrough: ZyVersa's New Alzheimer's Treatment Targets Brain Inflammation With Promising Results - StockTitan
ZyVersa secures $2 million in funding for drug development By Investing.com - Investing.com Canada
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market - GlobeNewswire
ZyVersa Therapeutics announces pricing of $2M private placement - MSN
ZyVersa secures $2 million in funding for drug development - Investing.com India
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
Healthcare Fund Backs ZyVersa With $2M Investment: Key Terms Revealed - StockTitan
ZVSA stock plunges to 52-week low, touches $0.94 amid market challenges - Investing.com Canada
ZVSA stock plunges to 52-week low, touches $0.94 amid market challenges By Investing.com - Investing.com South Africa
Wall Street Set to Open on Flat Note Wednesday as Investors Look for Signs of Tariff Relief - TradingView
ZyVersa’s IC 100 shows promise in heart failure treatment By Investing.com - Investing.com South Africa
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Di - The Manila Times
ZyVersa’s IC 100 shows promise in heart failure treatment - Investing.com
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Major Gestational Diabetes Market Trend 2025-2034: Advancements In Diagnostic Solutions For Early Detection... - WhaTech
Larchmont broker accused of years-long insider trading scheme - Westfair Online
Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara - Barchart
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Rises By 1,291.0% - Defense World
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Decrease in Short Interest - Defense World
Blaize Debuts on NASDAQ: First AI IPO of 2025 Hits $1.2B Valuation in Historic SPAC Deal - StockTitan
2024 Research Report: Global Celiac Disease Treatment - GlobeNewswire
Analysts Provide An Important Insights On ZyVersa Therapeutics Inc (ZVSA) - Stocks Register
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco - The Manila Times
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco - GlobeNewswire
ZyVersa to Showcase Breakthrough Kidney Disease Drug at JPM Healthcare Conference 2025 - StockTitan
ZVSA stock touches 52-week low at $1.03 amid sharp annual decline - Investing.com Canada
OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR - MSN
ZyVersa reports progress on stroke-related heart injury treatment By Investing.com - Investing.com Nigeria
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zyversa Therapeutics Inc Stock (ZVSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):